Patient, disease, and transplantation characteristics and posttransplantation outcomes
Characteristics . | UCB . | MSD . | P . |
|---|---|---|---|
| Patients | |||
| No. | 9 | 12 | |
| Age, y, median (range) | 28 (19-45) | 42 (23-58) | .02 |
| Male, no. (%) | 4 (44) | 8 (67) | .31 |
| Histology, no. (%) | |||
| Nodular sclerosing | 9 (100) | 11 (92) | .38 |
| Lymphocyte predominant | 0 | 1 (8) | |
| Disease characteristics at initial diagnosis | |||
| Ann Arbor stages, no. (%) | |||
| 1-2 | 3 (33) | 2 (17) | .27 |
| 3-4 | 6 (67) | 10 (83) | |
| B symptoms, no. (%) | 6 (67) | 7 (58) | .68 |
| Extranodal disease, no. (%) | 2 (22) | 1 (8) | .37 |
| Duration of CR1, mo, median (range)* | 4 (3-9) | 9 (4-60) | .03 |
| Disease characteristics at pretransplantation relapse | |||
| Ann Arbor stages, no. (%) | |||
| 1-2 | 4 (44) | 4 (33) | .70 |
| 3-4 | 5 (56) | 8 (67) | |
| B symptoms, no. (%) | 3 (33) | 6 (50) | .45 |
| Extranodal disease, no. (%) | 3 (33) | 5 (42) | .70 |
| No. total previous chemo regimens, median (range) | 4 (3-5) | 4 (3-7) | .97 |
| Previous ASCT, no. (%) | 7 (78) | 7 (58) | .35 |
| Post-ASCT CR duration, mo, median (range) | 6 (3-36) | 11 (4-54) | .56 |
| Transplantation characteristics | |||
| Time from diagnosis to allo-SCT, mo, median (range) | 28 (16-83) | 22 (11-154) | .78 |
| Disease status at allo-SCT, no. (%) | |||
| Primary refractory | 2 (22) | 2 (17) | .90 |
| Relapses 1-2 | 4 (44) | 5 (42) | |
| Relapse 3+ | 3 (33) | 5 (42) | |
| Residual disease present at allo-SCT, no. (%) | 8 (89) | 12 (100) | .24 |
| Conditioning regimen, no. (%) | |||
| Bu/Flu/TBI | 2 (22) | 6 (50) | .20 |
| Cy/Flu/TBI | 7 (78) | 6 (50) | |
| HLA 1-2 antigen mismatch, no. (%) | 9 (100) | 1 (8) | < .01 |
| Cell dose × 107 NC/kg, median (range) | 3.8 (2.3-5.3) | 10.0 (7.9-16.4) | < .01 |
| Posttransplantation outcomes | |||
| Time to neutrophil engraftment, d, median (range) | 10 (6-28) | 7 (5-12) | .02 |
| Complete donor chimerism, no. (%) | |||
| Day 21 | 6 (67) | 12 (100) | .06 |
| Day 60 | 9 (100) | 12 (100) | |
| Acute GVHD, no. (%) | |||
| Grades 2-4 | 6 (67) | 7 (58) | .70 |
| Grades 3-4 | 3 (33) | 4 (33) | .99 |
| Chronic GVHD, no. (%) | 1 (11) | 4 (33) | .24 |
| CR after allo-SCT, no. (%) | 8 (89) | 9 (75) | .42 |
| TRM, no. (%) | |||
| 100 d | 1 (11) | 2 (17) | .80 |
| 180 d | 2 (22) | 3 (25) | .88 |
| Follow-up after allo-SCT, mo, median (range) | 17 (4-51) | 24 (9-53) | |
| 2-y PFS rate, % (95% CI) | 25 (0-55) | 20 (0-44) | .67 |
| 2-y OS rate, % (95% CI) | 51 (16-86) | 48 (19-77) | .93 |
Characteristics . | UCB . | MSD . | P . |
|---|---|---|---|
| Patients | |||
| No. | 9 | 12 | |
| Age, y, median (range) | 28 (19-45) | 42 (23-58) | .02 |
| Male, no. (%) | 4 (44) | 8 (67) | .31 |
| Histology, no. (%) | |||
| Nodular sclerosing | 9 (100) | 11 (92) | .38 |
| Lymphocyte predominant | 0 | 1 (8) | |
| Disease characteristics at initial diagnosis | |||
| Ann Arbor stages, no. (%) | |||
| 1-2 | 3 (33) | 2 (17) | .27 |
| 3-4 | 6 (67) | 10 (83) | |
| B symptoms, no. (%) | 6 (67) | 7 (58) | .68 |
| Extranodal disease, no. (%) | 2 (22) | 1 (8) | .37 |
| Duration of CR1, mo, median (range)* | 4 (3-9) | 9 (4-60) | .03 |
| Disease characteristics at pretransplantation relapse | |||
| Ann Arbor stages, no. (%) | |||
| 1-2 | 4 (44) | 4 (33) | .70 |
| 3-4 | 5 (56) | 8 (67) | |
| B symptoms, no. (%) | 3 (33) | 6 (50) | .45 |
| Extranodal disease, no. (%) | 3 (33) | 5 (42) | .70 |
| No. total previous chemo regimens, median (range) | 4 (3-5) | 4 (3-7) | .97 |
| Previous ASCT, no. (%) | 7 (78) | 7 (58) | .35 |
| Post-ASCT CR duration, mo, median (range) | 6 (3-36) | 11 (4-54) | .56 |
| Transplantation characteristics | |||
| Time from diagnosis to allo-SCT, mo, median (range) | 28 (16-83) | 22 (11-154) | .78 |
| Disease status at allo-SCT, no. (%) | |||
| Primary refractory | 2 (22) | 2 (17) | .90 |
| Relapses 1-2 | 4 (44) | 5 (42) | |
| Relapse 3+ | 3 (33) | 5 (42) | |
| Residual disease present at allo-SCT, no. (%) | 8 (89) | 12 (100) | .24 |
| Conditioning regimen, no. (%) | |||
| Bu/Flu/TBI | 2 (22) | 6 (50) | .20 |
| Cy/Flu/TBI | 7 (78) | 6 (50) | |
| HLA 1-2 antigen mismatch, no. (%) | 9 (100) | 1 (8) | < .01 |
| Cell dose × 107 NC/kg, median (range) | 3.8 (2.3-5.3) | 10.0 (7.9-16.4) | < .01 |
| Posttransplantation outcomes | |||
| Time to neutrophil engraftment, d, median (range) | 10 (6-28) | 7 (5-12) | .02 |
| Complete donor chimerism, no. (%) | |||
| Day 21 | 6 (67) | 12 (100) | .06 |
| Day 60 | 9 (100) | 12 (100) | |
| Acute GVHD, no. (%) | |||
| Grades 2-4 | 6 (67) | 7 (58) | .70 |
| Grades 3-4 | 3 (33) | 4 (33) | .99 |
| Chronic GVHD, no. (%) | 1 (11) | 4 (33) | .24 |
| CR after allo-SCT, no. (%) | 8 (89) | 9 (75) | .42 |
| TRM, no. (%) | |||
| 100 d | 1 (11) | 2 (17) | .80 |
| 180 d | 2 (22) | 3 (25) | .88 |
| Follow-up after allo-SCT, mo, median (range) | 17 (4-51) | 24 (9-53) | |
| 2-y PFS rate, % (95% CI) | 25 (0-55) | 20 (0-44) | .67 |
| 2-y OS rate, % (95% CI) | 51 (16-86) | 48 (19-77) | .93 |
Excludes 2 patients with primary refractory disease in each group